vs
ASTRONICS CORP（ATRO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
ASTRONICS CORP的季度营收约是Orthofix Medical Inc.的1.1倍（$240.1M vs $219.9M），ASTRONICS CORP同比增速更快（15.1% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $15.8M），过去两年ASTRONICS CORP的营收复合增速更高（13.9% vs 8.0%）
Astronics Corporation是一家成立于1968年的美国航空航天电子企业，总部位于纽约州东奥罗拉，在纳斯达克上市，股票代码为ATRO。该公司专注于军用、商用及公务机的照明与电子系统集成业务，同时还提供半导体测试系统，在相关领域拥有较高知名度。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ATRO vs OFIX — 直观对比
营收规模更大
ATRO
是对方的1.1倍
$219.9M
营收增速更快
ATRO
高出13.1%
2.0%
自由现金流更多
OFIX
多$1.0M
$15.8M
两年增速更快
ATRO
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $240.1M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 33.3% | 71.1% |
| 营业利润率 | 14.8% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 15.1% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $0.82 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATROOFIX
| Q4 25 | $240.1M | $219.9M | ||
| Q3 25 | $211.4M | $205.6M | ||
| Q2 25 | $204.7M | $203.1M | ||
| Q1 25 | $205.9M | $193.6M | ||
| Q4 24 | $208.5M | $215.7M | ||
| Q3 24 | $203.7M | $196.6M | ||
| Q2 24 | $198.1M | $198.6M | ||
| Q1 24 | $185.1M | $188.6M |
净利润ATROOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-11.1M | $-22.8M | ||
| Q2 25 | $1.3M | $-14.1M | ||
| Q1 25 | $9.5M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-11.7M | $-27.4M | ||
| Q2 24 | $1.5M | $-33.4M | ||
| Q1 24 | $-3.2M | $-36.0M |
毛利率ATROOFIX
| Q4 25 | 33.3% | 71.1% | ||
| Q3 25 | 30.5% | 72.2% | ||
| Q2 25 | 25.8% | 68.7% | ||
| Q1 25 | 29.5% | 62.8% | ||
| Q4 24 | 29.8% | 69.0% | ||
| Q3 24 | 27.1% | 68.7% | ||
| Q2 24 | 28.0% | 67.8% | ||
| Q1 24 | 25.7% | 67.5% |
营业利润率ATROOFIX
| Q4 25 | 14.8% | 0.2% | ||
| Q3 25 | 10.9% | -8.3% | ||
| Q2 25 | 2.3% | -7.9% | ||
| Q1 25 | 6.4% | -25.2% | ||
| Q4 24 | 4.3% | -5.3% | ||
| Q3 24 | 4.1% | -9.6% | ||
| Q2 24 | 3.8% | -12.5% | ||
| Q1 24 | 0.9% | -15.6% |
净利率ATROOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -5.2% | -11.1% | ||
| Q2 25 | 0.6% | -6.9% | ||
| Q1 25 | 4.6% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -5.8% | -13.9% | ||
| Q2 24 | 0.8% | -16.8% | ||
| Q1 24 | -1.7% | -19.1% |
每股收益（稀释后）ATROOFIX
| Q4 25 | $0.82 | $-0.05 | ||
| Q3 25 | $-0.31 | $-0.57 | ||
| Q2 25 | $0.04 | $-0.36 | ||
| Q1 25 | $0.26 | $-1.35 | ||
| Q4 24 | $-0.07 | $-0.76 | ||
| Q3 24 | $-0.34 | $-0.71 | ||
| Q2 24 | $0.04 | $-0.88 | ||
| Q1 24 | $-0.09 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.2M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $140.1M | $450.0M |
| 总资产 | $706.7M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATROOFIX
| Q4 25 | $18.2M | $82.0M | ||
| Q3 25 | $13.5M | $62.9M | ||
| Q2 25 | $13.5M | $65.6M | ||
| Q1 25 | $24.8M | $58.0M | ||
| Q4 24 | $9.3M | $83.2M | ||
| Q3 24 | $5.2M | $30.1M | ||
| Q2 24 | $2.9M | $26.4M | ||
| Q1 24 | $5.3M | $27.0M |
总债务ATROOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益ATROOFIX
| Q4 25 | $140.1M | $450.0M | ||
| Q3 25 | $108.9M | $442.5M | ||
| Q2 25 | $271.6M | $458.3M | ||
| Q1 25 | $266.8M | $458.3M | ||
| Q4 24 | $256.1M | $503.1M | ||
| Q3 24 | $249.2M | $525.9M | ||
| Q2 24 | $257.9M | $546.0M | ||
| Q1 24 | $251.7M | $570.3M |
总资产ATROOFIX
| Q4 25 | $706.7M | $850.6M | ||
| Q3 25 | $682.2M | $832.6M | ||
| Q2 25 | $646.7M | $837.2M | ||
| Q1 25 | $662.2M | $823.1M | ||
| Q4 24 | $648.8M | $893.3M | ||
| Q3 24 | $651.6M | $867.9M | ||
| Q2 24 | $644.9M | $882.0M | ||
| Q1 24 | $630.0M | $906.0M |
负债/权益比ATROOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $15.8M | $16.8M |
| 自由现金流率自由现金流/营收 | 6.6% | 7.6% |
| 资本支出强度资本支出/营收 | 4.9% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $43.1M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ATROOFIX
| Q4 25 | $27.6M | $27.7M | ||
| Q3 25 | $34.2M | $12.4M | ||
| Q2 25 | $-7.6M | $11.6M | ||
| Q1 25 | $20.6M | $-18.4M | ||
| Q4 24 | $26.4M | $23.7M | ||
| Q3 24 | $8.4M | $11.7M | ||
| Q2 24 | $-6.3M | $9.0M | ||
| Q1 24 | $2.0M | $-18.6M |
自由现金流ATROOFIX
| Q4 25 | $15.8M | $16.8M | ||
| Q3 25 | $21.0M | $2.5M | ||
| Q2 25 | $-12.2M | $4.5M | ||
| Q1 25 | $18.5M | $-25.1M | ||
| Q4 24 | $23.2M | $15.2M | ||
| Q3 24 | $6.5M | $6.3M | ||
| Q2 24 | $-8.1M | $-360.0K | ||
| Q1 24 | $439.0K | $-29.1M |
自由现金流率ATROOFIX
| Q4 25 | 6.6% | 7.6% | ||
| Q3 25 | 9.9% | 1.2% | ||
| Q2 25 | -6.0% | 2.2% | ||
| Q1 25 | 9.0% | -13.0% | ||
| Q4 24 | 11.1% | 7.0% | ||
| Q3 24 | 3.2% | 3.2% | ||
| Q2 24 | -4.1% | -0.2% | ||
| Q1 24 | 0.2% | -15.4% |
资本支出强度ATROOFIX
| Q4 25 | 4.9% | 4.9% | ||
| Q3 25 | 6.2% | 4.8% | ||
| Q2 25 | 2.2% | 3.5% | ||
| Q1 25 | 1.0% | 3.5% | ||
| Q4 24 | 1.5% | 4.0% | ||
| Q3 24 | 0.9% | 2.7% | ||
| Q2 24 | 0.9% | 4.7% | ||
| Q1 24 | 0.9% | 5.6% |
现金转化率ATROOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -5.81× | — | ||
| Q1 25 | 2.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.08× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRO
| Product Line Electrical Power And Motion | $113.8M | 47% |
| Product Line Avionics | $32.0M | 13% |
| Military Aircraft | $28.0M | 12% |
| General Aviation | $22.3M | 9% |
| Government And Defense | $20.5M | 9% |
| Product Line Systems Certification | $13.2M | 6% |
| Product Line Structures | $3.7M | 2% |
| Product Line Other | $2.3M | 1% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
